{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:46:47Z","timestamp":1785743207956,"version":"3.56.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>AJ1-11095, a type II JAK2 inhibitor being developed for myelofibrosis, led to impressive clinical responses in a recent phase I study, suggesting that the drug, and perhaps the rest of its still-investigational class, could prove better than currently approved type I JAK2 inhibitors.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0074","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:56:35Z","timestamp":1782921395000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Type II JAK2 Inhibitor Gets Off to a Strong Start"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,7,1]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2026-0074\/786361\/Type-II-JAK2-Inhibitor-Gets-Off-to-a-Strong","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787100\/Type-II-JAK2-Inhibitor-Gets-Off-to-a-Strong","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787100\/Type-II-JAK2-Inhibitor-Gets-Off-to-a-Strong","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:14:56Z","timestamp":1785741296000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/8\/OF1\/787100\/Type-II-JAK2-Inhibitor-Gets-Off-to-a-Strong"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0074","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}